Historical record - last NADAC publication: 6/19/2019
Product Information
THERAFLU MS SEVERE COLD PCKT is a brand product labeled by Haleon US Holdings LLC, priced at $0.9107 per EA under NDC 00067642606. Its NADAC has been published 104 times since Jun 20, 2018.
The High Outlier badge above means this manufacturer's average price in the ACETAMINOPHEN, DEXTROMETHORPHAN HBr, PHENYLEPHRINE HCl market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
500; 20; 10 mg/237mL; mg/237mL; mg/237mL
Manufacturer
Haleon US Holdings LLCNDC
00067642606
Classification
Brand
Dosage Form
POWDER, FOR SOLUTION
Route
ORAL
Last Updated
6/19/2019
Approval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
7/1/2014
Pharmacological Classes
Price Statistics
The NADAC for THERAFLU MS SEVERE COLD PCKT has been published 104 times since Jun 20, 2018, and over the history we have for it it has risen 6.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9107 per EA |
|---|---|
| All-time high | $0.9107 (Jun 10, 2020) |
| All-time low | $0.8432 (Feb 20, 2019) |
| Median price | $0.8945 |
| Average price | $0.8868 |
| Largest weekly change | +5.6% (Jun 19, 2019) |
| Weeks tracked | 104 |
| Tracking since | Jun 20, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the ACETAMINOPHEN, DEXTROMETHORPHAN HBr, PHENYLEPHRINE HCl market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of THERAFLU MS SEVERE COLD PCKT?
The current National Average Drug Acquisition Cost (NADAC) for THERAFLU MS SEVERE COLD PCKT, manufactured by Haleon US Holdings LLC, is $0.9107 per EA (NDC 00067642606), effective Jun 10, 2020.
How has the price of THERAFLU MS SEVERE COLD PCKT changed over time?
Over the history we have for it, the NADAC for THERAFLU MS SEVERE COLD PCKT has risen 6.6%. It has been tracked across 104 weekly CMS publications since Jun 20, 2018.
What are the highest and lowest recorded NADAC prices for THERAFLU MS SEVERE COLD PCKT?
Since Jun 20, 2018, the NADAC for THERAFLU MS SEVERE COLD PCKT has ranged from a low of $0.8432 (Feb 20, 2019) to a high of $0.9107 (Jun 10, 2020), with a median of $0.8945 per EA.
Are there cheaper alternatives to THERAFLU MS SEVERE COLD PCKT?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of THERAFLU MS SEVERE COLD PCKT, so no direct lower-cost alternative is listed.
Who manufactures THERAFLU MS SEVERE COLD PCKT?
THERAFLU MS SEVERE COLD PCKT (NDC 00067642606) is labeled by Haleon US Holdings LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification